Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Harmony Biosciences sells WAKIX, a once-daily pill that helps people with narcolepsy stay awake during the day.
Harmony Biosciences is a small drug company with essentially one job: selling a pill called WAKIX to people in the United States who have narcolepsy, a rare brain condition that makes people fall asleep uncontrollably during the day. WAKIX is designed to keep them awake, and it is the company's whole business. Harmony does not run labs hunting for brand-new molecules; it looks for promising medicines that already exist or are in late-stage testing, buys the rights to them, and then uses its own sales force to get them into the hands of sleep doctors and their patients.
The drug itself has an unusual history. It is a medicine called pitolisant that was first developed overseas, and Harmony licensed the U.S. rights to it and got it approved by the FDA in 2019 for excessive daytime sleepiness in adults with narcolepsy. Since then the label has grown: it now covers children with narcolepsy too, and adults with obstructive sleep apnea whose daytime sleepiness persists despite treatment. That matters because each new group of patients widens the pool of people a small sales team can call on. WAKIX works differently from older stimulant-style narcolepsy drugs, which helps it stand out, and it is taken once a day as a tablet. The business is tiny in headcount but serious in revenue. Harmony reported roughly $700 million in net revenue in 2024, almost all of it from WAKIX, and the company is based in Plymouth Meeting, Pennsylvania. The appeal to investors is simple: rare-disease drugs face little competition, insurance plans tend to cover them, and patients usually stay on them for years. The risk is just as simple. Harmony is a one-product company, so anything that threatens WAKIX — a patent fight, a pricing squeeze, a safety scare, or a rival narcolepsy drug — hits the whole company at once.
That is why Harmony is trying to buy itself some insurance. It has been adding pipeline drugs and smaller acquisitions aimed at other rare neurological conditions, in the hope of one day having a second big seller. It also bought back stock in recent years, a sign management thought its own shares were cheap. But for now, the story is a single pill, sold by a lean sales force, to a patient group small enough that most people have never heard of it.
Saved answer · last researched 15 Nov 2026